P76.43 Co-occurring genomic alterations and treatment outcomes in patients with EGFR exon 20 insertion positive NSCLC
C. Kim(Georgetown University), G. Lopes(University of Miami), Hirva Mamdani(Wayne State University), Rebecca Feldman(Caris Life Sciences (United States)), Ari M. Vanderwalde(West Cancer Center), Stephen V. Liu(Georgetown University), Alexander I. Spira(Virginia Cancer Specialists), Sachin Gopalkrishna Pai(USA Mitchell Cancer Institute), Agnieszka Woźniak(VIB-KU Leuven Center for Cancer Biology), Misako Nagasaka(University of California, Irvine), Jorge J. Nieva(University of Southern California), Chukwuemeka Ikpeazu(Sylvester Comprehensive Cancer Center), Luis E. Raez(Florida International University), A. Herrmann(University of Southern California)
Cited by 2
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k